Susquehanna International Group
CRSP icon

Susquehanna International Group’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna International Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.2M Sell
487,300
-206,600
-30% -$10.9M ﹤0.01% 2043
2025
Q4 		$36.4M Sell
693,900
-11,600
-2% -$695K ﹤0.01% 1631
2025
Q3 		$45.7M Buy
705,500
+213,600
+43% +$12.3M 0.01% 1412
2025
Q2 		$23.9M Buy
491,900
+83,300
+20% +$3.22M ﹤0.01% 1825
2025
Q1 		$13.9M Sell
408,600
-126,000
-24% -$5.34M ﹤0.01% 2128
2024
Q4 		$21M Sell
534,600
-70,100
-12% -$3.31M ﹤0.01% 1825
2024
Q3 		$28.4M Buy
604,700
+124,300
+26% +$6.31M 0.01% 1502
2024
Q2 		$25.9M Sell
480,400
-85,100
-15% -$4.92M ﹤0.01% 1475
2024
Q1 		$38.5M Buy
565,500
+123,200
+28% +$8.82M 0.01% 1217
2023
Q4 		$27.7M Buy
442,300
+211,200
+91% +$11.7M 0.01% 1470
2023
Q3 		$10.5M Sell
231,100
-31,300
-12% -$1.62M ﹤0.01% 2505
2023
Q2 		$14.7M Buy
262,400
+34,600
+15% +$1.96M ﹤0.01% 2048
2023
Q1 		$10.3M Buy
227,800
+27,200
+14% +$1.32M ﹤0.01% 2411
2022
Q4 		$8.15M Sell
200,600
-3,100
-2% -$164K ﹤0.01% 2542
2022
Q3 		$13.3M Sell
203,700
-133,100
-40% -$9.65M ﹤0.01% 1835
2022
Q2 		$20.5M Sell
336,800
-45,100
-12% -$2.65M 0.01% 1440
2022
Q1 		$24M Sell
381,900
-154,400
-29% -$9.7M ﹤0.01% 1543
2021
Q4 		$40.6M Sell
536,300
-98,400
-16% -$8.6M 0.01% 1249
2021
Q3 		$71M Sell
634,700
-21,300
-3% -$2.68M 0.01% 956
2021
Q2 		$106M Sell
656,000
-91,700
-12% -$11.2M 0.01% 760
2021
Q1 		$91.1M Buy
747,700
+269,500
+56% +$40.7M 0.01% 776
2020
Q4 		$73.2M Buy
478,200
+254,400
+114% +$30.1M 0.01% 808
2020
Q3 		$18.7M Sell
223,800
-117,500
-34% -$10.4M ﹤0.01% 1544
2020
Q2 		$25.1M Buy
341,300
+124,900
+58% +$7.3M 0.01% 1243
2020
Q1 		$9.18M Sell
216,400
-182,400
-46% -$9.42M ﹤0.01% 1825
2019
Q4 		$24.3M Buy
398,800
+197,400
+98% +$10.8M 0.01% 1254
2019
Q3 		$8.26M Sell
201,400
-57,800
-22% -$2.76M ﹤0.01% 2178
2019
Q2 		$12.2M Sell
259,200
-116,800
-31% -$4.67M ﹤0.01% 1700
2019
Q1 		$13.4M Buy
376,000
+33,600
+10% +$1.16M 0.01% 1496
2018
Q4 		$9.78M Sell
342,400
-190,100
-36% -$6.61M ﹤0.01% 1623
2018
Q3 		$23.6M Sell
532,500
-20,400
-4% -$1.07M 0.01% 1199
2018
Q2 		$32.5M Buy
552,900
+95,800
+21% +$5.46M 0.01% 934
2018
Q1 		$20.9M Buy
457,100
+398,200
+676% +$16.4M 0.01% 1177
2017
Q4 		$1.38M Buy
58,900
+5,600
+11% +$106K ﹤0.01% 4602
2017
Q3 		$952K Buy
53,300
+33,300
+167% +$604K ﹤0.01% 5364
2017
Q2 		$320K Buy
+20,000
New +$330K ﹤0.01% 7463

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group's CRSP Position: Q1 2026 in Review

Susquehanna International Group reduced its CRISPR Therapeutics (CRSP) stake by 31% in Q1 2026, selling an estimated $13.7M and leaving 593,406 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Susquehanna International Group first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $57M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Susquehanna International Group held 593,406 shares of CRISPR Therapeutics worth $28.2M as of Q1 2026.
  • Susquehanna International Group sold 260,565 CRISPR Therapeutics shares in Q1 2026, an estimated $13.7M.
  • CRISPR Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1806 holding.
  • Susquehanna International Group first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • Susquehanna International Group's CRISPR Therapeutics position peaked at $57M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.